Curated clinical source

NTRK fusion melanoma

What to ask when melanoma testing reports an NTRK fusion.

NTRK fusions are rare but can be important because some NTRK-targeted therapies are approved in tumor-agnostic contexts. The exact test result and country-specific approval status matter.

What to clarify

• Is the result a true NTRK fusion?
• Which NTRK gene and fusion partner were reported?
• Was the test DNA-based, RNA-based, or both?
• Does the oncology team consider an NTRK-targeted therapy or trial relevant?

Questions to ask

• Is this result actionable in our country?
• Should the result be confirmed with another test?
• Are there tumor-agnostic therapy options or trials to discuss?